Dr. Carrillo is Chief Science Officer, Medical and Scientific Relations, at the Alzheimer's Association. At the Association, Dr. Carrillo has a wide range of responsibilities, inclurding oversight of the Association's grantmaking process and communication of scientific findings within and outside of the organization.
Dr. Carrillo oversees the international science division for the Alzheimer's Association, and also manages several Association initiatives. One of these is the Alzheimer's Association International Conference, the largest international discussion on Alzheimer's and related dementias in the world. Another is the Alzheimer's Association Research Roundtable, which provides a forum for pharmaceutical companies to discuss trends in Alzheimer research and therapeutic targets. Dr. Carrillo manages the World-Wide Alzheimer's Disease Neuroimaging Initiative (WW-ADNI), which is a multi-country research effort aimed at finding biomarkers for early detection of Alzheimer's.
Dr. Carrillo is on the Advisory Committee for the World Health Organization Dementia Setting Priorities & Portfolio Analysis. She leads the Alzheimer's Association's GAAIN project, which is creating a global federated network to support all publicly accessible data in dementia. In 2016, Dr. Carrillo joined the Governing Board of the Global Brain Health Institute, which is reducing the and impact of dementia around the world by training and supporting a new generation of leaders to translate research evidence into effective policy and practice. Also in 2016, Dr. Carrillo became a member of the American Heart Association's Research Committee.
Dr. Carrillo has published extensively on early diagnosis and biomarker standardization efforts in Alzheimer's disease, in addition to global challenges to Alzheimer's and dementia research progress. She is co-author of the NIA-AA revised criteria for diagnosis of Alzheimer's, and the Appropriate Use Criteria fo